Simplify Life®
with Omnipod® 5
Proactively helps to correct highs and protect from lows1,2,3
No multiple daily injections, tubes, or fingersticks*
Cleared for people with type 1 diabetes ages 2 years and older and type 2 diabetes ages 18 years and older
Three simple parts
The Omnipod 5 Pod, compatible CGM, and Omnipod 5 App on a Controller or compatible smartphone are in constant communication, giving you automatic insulin adjustments every five minutes.
Always adjusting so you don’t have to
With SmartAdjust™ technology, Omnipod 5 uses your CGM value and trend to automatically increase, decrease, or pause insulin delivery every 5 minutes.
Hear real stories
“Having control over my diabetes and my numbers—I’ve found this new confidence that I didn’t have before.”
Morgan M.
Omnipod 5 User
Get started today
Omnipod 5 is now integrated with Dexcom G6 and G7. If you are new to Omnipod, you may have coverage for Omnipod 5 with Dexcom G7 integration through select mail-order pharmacies.
Omnipod 5 is available exclusively through the pharmacy channel, which means you can make the switch from multiple daily injections, a tubed pump, or another Omnipod product at almost any time*. Simply fill out the form to get started.
If you are already on Omnipod 5, visit the New Omnipod 5 Compatible Devices page to learn more.
Looking for more information
about Omnipod 5?
Check out the Omnipod 5 FAQs or “How to” video tutorials
*Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
†For a list of compatible smartphone devices visit omnipod.com/compatibility.
1. Study in 80 people with T1D aged 2 5.9 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 = 57.2% vs. 68.1%. Average time in Target Glucose range (6AM 12AM) from CGM in standard therapy vs Omnipod 5 = 58.2% vs. 64.3%. Average time in Tar get Glucose range (12AM 6AM) from CGM in standard therapy vs. Omnipod 5 = 60.6% vs 82.4%. Average overnight time (12AM 6AM) with high blood glucose in adults/adol escents and children for standard therapy vs. Omnipod 5 = 32.1% vs. 20.7%; 42.2% vs. 20.7%. Average day time (6AM 12AM) with high blood glucose in adults/adolescents and children for standard therapy vs. Omnip od 5 = 32.6% vs. 26.1%; 46.4% vs. 33.4%. Median overnight time (12AM 6AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 2.07% vs. 0.82%; 0.78% vs. 0.78%. Media n d ay time (6AM 12AM) with low blood glucose in adults/adolescents and children for standard therapy vs. Omnipod 5 = 1.91% vs. 1.08%; 1.17% vs. 1.62%. Average A1c in standard therapy vs. Omnipod 5 = 7.4% vs. 6.9%. Sherr JL, et al. Diabetes Care (2022).
2. Study in 240 people with T1D aged 6 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time in Target Glucose range (from CGM) for standard therapy vs Omnipod 5 in adults/adolescents and children = 64.7% vs. 73.9%; 52.5% vs. 68.0%. Average day time (6AM 12AM) in Targe t Glucose range (from CGM) in adults/adolescents and children for standard therapy vs Omnipod 5 = 64.8% vs. 72.5%; 51.5% vs. 64.6%. Average overnight (12AM 6AM) in Target Glucose range (from CGM) in adults/adole scents and children for standard therapy vs Omnipod 5 = 64.3% vs. 78.1%; 55.3% vs. 78.1%. Average time with high blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 38.4% vs. 16.9%. Average time wit h h igh blood during daytime from CGM in standard therapy vs. Omnipod 5 = 39.7% vs. 33.7%. Average time with low blood glucose overnight from CGM in standard therapy vs. Omnipod 5 = 3.41% vs. 2.13%. Ave rage time with low blood glucose during daytime from CGM in standard therapy vs. Omnipod 5 = 3.44% vs. 2.57%. Average A1c in adults/adolescents and children, standard therapy vs. Omnipod 5 = 7.16% vs 6.78%; 7.67% vs 6.99%. Brown et al. Diabetes Care (2021).
3. Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-mo Omnipod 5 = 0.2%, P<001. Mean time >180 mg/dL as measured by CGM: ST = 54%, 3-mo Omnipod 5 = 34%, P<0.001. Mean HbA1c: baseline vs. 13-week Omnipod 5: 8.2% vs. 7.4%, P<0.001. Comparison is relative change.
Risk Statement
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older and type 2 diabetes mellitus in persons 18 years of age and older.
The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 2 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®.
The Omnipod 5 ACE Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 ACE Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values.
The Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value.
WARNING: SmartAdjust technology should NOT be used by anyone under the age of 2 years old. SmartAdjust technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.
WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.